A Phase I/IIa Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites
Latest Information Update: 07 Jan 2022
At a glance
- Drugs BSG 001 (Primary)
- Indications Malignant ascites; Malignant pleural effusion
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioSyngen
- 18 Nov 2018 New trial record